FDA Safety Request Delays Novartis Phase III Program For MS Agent FTY720
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis is delaying the start of Phase III clinical trials for its oral multiple sclerosis treatment FTY720 until the fourth quarter following a request for a safety analysis from FDA